Ketamine in borderline personality disorder
The aim of this research is to see whether the antidepressant ketamine can reduce suicidality in people with Borderline Personality Disorder (BPD). BPD has a rate of completed suicide that is equivalent to depression or schizophrenia. There is actually no drug that can be used to treat BPD.
Ketamine is an FDA-approved anesthetic that has been shown to help people with Major Depressive Disorder reduce suicidality and improve their mood (MDD). Despite the fact that their symptoms are similar, successful therapies for MDD and BPD vary. This research explores whether ketamine reduces suicidality and enhances mood in people with BPD.
This trial will also measure several other outcomes after ketamine versus placebo in BPD: adverse events, BPD symptoms, pain, social cognition, and neuroplasticity.